Roche last week said it plans to acquire 454 Life Sciences in a deal valued at up to $154.9 million, but the Swiss drug and diagnostics company would have been happy to continue the firms’ existing marketing and distribution alliance had CuraGen not decided to sell its stake in 454, according to a Roche executive.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.